Peter Besler

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Peter Besler (born October 5, 1963) is an investment advisor and author residing in Toronto, Ontario, Canada. Born in Waterloo, Ontario, Besler is known for raising public funds in order to finance Canadian companies conducting research into the treatment of serious and terminal illnesses. Since 1986, his efforts have benefited numerous biotechnology and medical research companies conducting pre-clinical and phase I, II, and III human clinical trials.[1]


Besler was as a co-op chemistry student at University of Waterloo. In 1982, he grew concerned that scientific research in Canada was inadequately funded.[2] He co-led the Progressive Conservative Party Campus Youth in 1983.[3] Switching his area of study, he graduated with a degree in Economics in 1986. Shortly after graduation, he moved to Toronto and studied investment banking under Gerszon Taichman.[4] In 1994, Besler traveled to China with the purpose of establishing in-vitro fertilization clinics with researchers from Cornell University.[5] In 2001, he became aware of promising research conducted by Dr. Ingrid Katz into a treatment for multiple sclerosis at the University of Edmonton. In 2003, he was instrumental in obtaining the financing required to receive Health Canada approval for advancing this research through phase II human clinical trials.[6] The trials received FDA fast track approval in 2008.[7]

Besler is involved in philanthropic and volunteer work for several Canadian charitable organizations.

Medical research[edit]

Besler's fundraising has financed areas of medical research including, scleroderma, diabetes, cardiovascular disease, prostate cancer, breast cancer and multiple sclerosis. He has directed his support towards researchers with promising results who no longer are receiving research grants from charitable organizations. "It is surprising to the public that most advanced research into treatments for serious illnesses is not funded by charities nor governments. Private investors are often the only source available to companies seeking to cover the enormous funding costs associated with clinical trials." Besler has stated.[8]

Investment advise[edit]

Besler has authored several books on finance and investment including "The PEARL Approach - Protected Effective Asset Risk Limitation investment strategy" and "Investment Advisor Training Guide".[9] In addition, Besler was a featured columnist in "Canadian Money Saver" with Morris I. Bubbis.[10] In 2012, Besler became the most widely read feature columnist for "The Northern Miner" newspaper[11] and "Mining Markets" magazine.[12]


  1. ^ Vasogen Inc.,, BioMS Medical Inc., Protox Therapeutics, Hemosol Biopharma Inc.
  2. ^ Federal Scientific Activities, Copyright Statistics Canada Ministry of Industry, ref. National Research Council (Canada), Catalogue No. 88-204-XPB ISSN 0824-0310 1988
  3. ^ University of Waterloo Alumni Directory, Second Edition 1990, Office of Alumni Affairs pg. 1:31
  4. ^ Bank of America Merrill Lynch Canada
  5. ^ The Center For Reproductive Medicine and Infertility (CRMI), Dr. Kangpu Xu, JAMA 281: 1701-1706
  6. ^ Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, Alberta, Canada Multiple Sclerosis, Vol. 14, No. 7, 872-879 (2008) doi:10.1177/1352458508089226
  7. ^, "A Study for Patients With Relapsing Remitting Multiple Sclerosis (MINDSET01)" Eli Lilly and Company, Trial Identifier NCT00869986
  8. ^ Ben Leeson (May 13, 2005). "Firm To Invest In Secondary Industry In North". The Daily Press. p. A8.
  9. ^ Government of Canada, Canadian Intellectual Property Office, reference 1046614
  10. ^ "Mining the Market", Morris I. Bubbis, Central Publishing, Ottawa ISBN 0-9690443-0-5
  11. ^ Northern Miner,
  12. ^ Mining Markets,